DE69722594D1 - Pulverförmiges arzneimittel enthaltend interzelluläres adhäsionsmolekül - Google Patents

Pulverförmiges arzneimittel enthaltend interzelluläres adhäsionsmolekül

Info

Publication number
DE69722594D1
DE69722594D1 DE69722594T DE69722594T DE69722594D1 DE 69722594 D1 DE69722594 D1 DE 69722594D1 DE 69722594 T DE69722594 T DE 69722594T DE 69722594 T DE69722594 T DE 69722594T DE 69722594 D1 DE69722594 D1 DE 69722594D1
Authority
DE
Germany
Prior art keywords
sicam
product containing
medicinal product
amount
adhesive molecule
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
DE69722594T
Other languages
English (en)
Other versions
DE69722594T2 (de
Inventor
J Mcnally
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Boehringer Ingelheim Pharmaceuticals Inc
Original Assignee
Boehringer Ingelheim Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=21757501&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DE69722594(D1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Boehringer Ingelheim Pharmaceuticals Inc filed Critical Boehringer Ingelheim Pharmaceuticals Inc
Publication of DE69722594D1 publication Critical patent/DE69722594D1/de
Application granted granted Critical
Publication of DE69722594T2 publication Critical patent/DE69722594T2/de
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0043—Nose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A61K38/1774—Immunoglobulin superfamily (e.g. CD2, CD4, CD8, ICAM molecules, B7 molecules, Fc-receptors, MHC-molecules)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/146—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Virology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Cell Biology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Otolaryngology (AREA)
  • Molecular Biology (AREA)
  • Pulmonology (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
DE69722594T 1996-03-06 1997-03-04 Pulverförmiges arzneimittel enthaltend interzelluläres adhäsionsmolekül Expired - Fee Related DE69722594T2 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US1294496P 1996-03-06 1996-03-06
US12944P 1996-03-06
PCT/US1997/003263 WO1997032596A1 (en) 1996-03-06 1997-03-04 Intercellular adhesion molecule powder formulation

Publications (2)

Publication Number Publication Date
DE69722594D1 true DE69722594D1 (de) 2003-07-10
DE69722594T2 DE69722594T2 (de) 2004-04-29

Family

ID=21757501

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69722594T Expired - Fee Related DE69722594T2 (de) 1996-03-06 1997-03-04 Pulverförmiges arzneimittel enthaltend interzelluläres adhäsionsmolekül

Country Status (8)

Country Link
US (1) US6365343B1 (de)
EP (1) EP0885010B1 (de)
JP (1) JP2000507221A (de)
AT (1) ATE242001T1 (de)
CA (1) CA2244894A1 (de)
DE (1) DE69722594T2 (de)
DK (1) DK0885010T3 (de)
WO (1) WO1997032596A1 (de)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP4493594B2 (ja) * 2003-03-04 2010-06-30 田辺三菱製薬株式会社 粉末経鼻投与製剤
WO2004100929A1 (en) 2003-05-12 2004-11-25 Synergia Pharma, Inc. Threo-dops controlled release formulation
US8158149B2 (en) * 2004-05-12 2012-04-17 Chelsea Therapeutics, Inc. Threo-DOPS controlled release formulation
GB2420707A (en) * 2004-10-11 2006-06-07 Nasaleze Patents Ltd Compositions for intranasal administration
KR20100059859A (ko) * 2007-09-11 2010-06-04 몬도바이오테크 래보래토리즈 아게 치료제로서의 ｃ형 나트륨이뇨 펩티드 단독 또는 뉴로펩티드 ａｆ와의 배합물의 용도

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0362531B1 (de) * 1988-09-01 1999-11-10 Bayer Corporation Menschliches Rhinovirusrezeptorprotein, das die Virusinfektionsanfälligkeit hemmt
US5235049A (en) * 1989-01-24 1993-08-10 Molecular Therapeutics, Inc. Nucleic acid sequences encoding a soluble molecule (SICAM-1) related to but distinct from ICAM-1
CA2008368C (en) * 1989-01-24 2003-04-08 Jeffrey Greve Soluble molecule related to but distinct from icam-1
DK0745852T3 (da) * 1989-03-16 2002-10-14 Blood Res Center Anvendelse af funktionelle derivater af intercellulær adhæsion-molekylet ICAM-1 i antiviral terapi
WO1991018010A1 (en) * 1990-05-15 1991-11-28 Swinburne Limited Inhibition of viral infection using intercellular adhesion molecule-1-like peptides and/or analogues thereof
GB9414966D0 (en) * 1994-07-26 1994-09-14 Danbiosyst Uk Pharmaceutical compositions for the nasal administration of antiviral agents
US5879712A (en) 1995-06-07 1999-03-09 Sri International Method for producing drug-loaded microparticles and an ICAM-1 dosage form so produced

Also Published As

Publication number Publication date
CA2244894A1 (en) 1997-09-12
ATE242001T1 (de) 2003-06-15
DK0885010T3 (da) 2003-09-15
EP0885010A1 (de) 1998-12-23
JP2000507221A (ja) 2000-06-13
US6365343B1 (en) 2002-04-02
WO1997032596A1 (en) 1997-09-12
EP0885010B1 (de) 2003-06-04
DE69722594T2 (de) 2004-04-29

Similar Documents

Publication Publication Date Title
YU57600A (sh) Derivarti biciklične hidroksaminske kiseline
MD1813B2 (en) Purified cyclodextrin derivatives of sulphoalkyl ethers or mixtures thereof, clathrate complex of cyclodextrin derivatives with medicamental content and pharmaceutical composition
SE9700135D0 (sv) New formulation
MX9605940A (es) Compuestos bioaromaticos que llevan un grupo adamantilo en orto, composiciones farmaceuticas y cosmeticas que los contienen y utilizaciones.
AU9062998A (en) Modified release multiple-units compositions of non-steroid anti-inflammatory drug substances (nsaids)
CA2224528A1 (fr) Composes stilbeniques a groupement adamantyl, compositions les contenant et utilisations
BR9803300A (pt) Formulação farmacêutica.
AP9801169A0 (en) N-hydroxy-B-sulfonyl propionamide derivatives.
CO5271759A1 (es) Formulacion en solucion que contiene una mezcla de disolventes
TR199500856A2 (tr) Nefesle ice cekilerek alinan farmasötik bilesim.
GB2332147A (en) Therapeutically active compositions
NO984376L (no) Mikrosfµrer av polysakkarid for administrering av medikamenter til lungene
BR0014939A (pt) Oligossacarìdeos, processo de preparação de oligossacarìdeos, composições farmacêuticas, e, utilização de oligossacarìdeos
NZ505919A (en) Nasal solutions
ATE291914T1 (de) Zolmitriptanhaltige arzneizusammensetzungen
IS5110A (is) Ný lyfjablanda til innöndunar með eðlisþyngd í lausu sem er frá 0,28 til 0,38 g/ml, sem inniheldur búdesóníð
AR021921A1 (es) Formulaciones farmaceuticas en aerosol que contienen fluoroalcanos y budesonido.
PT975348E (pt) Composicoes de tibolona estabilizadas
NO20005332L (no) 1,6-GPS-(6-O-α-D-glukopyranosyl-D-sorbit) og 1,1-GPM-(1-O-α-D-glukopyranosyl-D-mannit)-holdig sukkeralkoholblanding for bruk som terapeutisk aktivt stoff samt legemiddel inneholdende nevnte blanding
DE69722594D1 (de) Pulverförmiges arzneimittel enthaltend interzelluläres adhäsionsmolekül
HUP9801924A2 (hu) Nátrium/hidrogén-csere inhibitorokat és szív- és keringési zavarok kezelésére alkalmas hatóanyagokat tartalmazó gyógyszerkészítmény
NO20012351L (no) Farmasoytisk sammensetning for modifisert frigjoring av insulinsensibiliserende middel
CA2348474A1 (en) Pharmaceutically active composition and dispensing device
ES2176792T3 (es) Tabletas que contienen una resina de intercambio ionico.
HUP9802005A2 (hu) Nátrium/hidrogén-csere inhibitorok alkalmazása különböző anyagok által a szívre gyakorolt nem kívánt hatások csökkentésére alkalmas gyógyszerkészítmények előállítására

Legal Events

Date Code Title Description
8364 No opposition during term of opposition
8339 Ceased/non-payment of the annual fee